Fig. 1

PUS7 is overexpressed in CRC and significantly linked to poor prognosis in CRC patients. a Assessment of the relative PUS7 expression in diverse cancer subtypes (HPA024116 dataset). b Representative IHC staining of PUS7 expression in LUSC, LUAD, LIHC, THCA, BRCA, KIRC, ESCA, STAD, PAAD, and COAD tissues. c PUS7 expression trend at the mRNA level across different tumour samples and paired non-malignant tissues on the basis of the GEPIA data resource. d Meta-analysis of PUS7 gene expression in the context of five Oncomine data repositories, where coloured squares indicate the median rank for PUS7 (vs. non-malignant tissue) across 8 analyses: Gaspar Colon (1), Kaiser Colon (2), Skrzypczak Colorectal (3), Skrzypczak Colorectal 2 (4), TCGA Colorectal (5–8). The P value is given for the median-rank analysis. e-h PUS7 mRNA levels in CRC patients based on TCGA datasets from the Oncomine database. i qPCR analysis of PUS7 expression in 19 in-house collected CRC tissues. j Representative IHC staining and plot of IHC-scores of PUS7 expression in 57 in-house collected CRC tissues and neighbouring non-malignant tissues. k WB analysis of PUS7 protein expression in 7 CRC tissue pairs; GAPDH was used as the loading standard. N, neighbouring non-malignant tissues; T, tumour tissues. l IHC evaluation of CRC and non-malignant neighbouring tissues in a TMA and Kaplan–Meier analysis of the relationship of PUS7 expression with OS in individuals with CRC. m Representative IHC staining of PUS7 expression in neighbouring non-malignant tissues, primary CRC tissues, and metastatic CRC tissues. n Representative IHC staining of PUS7 expression in neighbouring non-malignant tissues, adenoma tissues, and CRC tissues. All the data are shown as the mean ± s.d. *P < 0.05, **P < 0.01, ***P < 0.001